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Abstract
Purpose The purpose of this study was to compare the
effects of cardiac resynchronization therapy (CRT) in elderly
patients (≥65 years) with younger patients and to assess the
impact of comorbidities in CRT remodeling response.
Methods This is a prospective study of 87 consecutive
patients scheduled for CRT who underwent clinical and
echocardiographic evaluation before and 6 months after
CRT. A reduction in left ventricular end-systolic volume
(LVESV) ≥15% after CRT defined remodeling responders,
and a reduction of at least one New York Heart Association
class defined clinical responders. Multivariate analysis was
used to identify independent predictors of non-response to
CRT in terms of reverse remodeling.
Results The mean age was 62±11 years, with 36 elderly
patients (41%). The baseline QRS duration was 145±
32 ms. After CRT, there were significant and similar
improvements of left ventricular (LV) ejection fraction,
LVESV, LV dP/dt, and mitral regurgitation jet area (JA)
between elderly (≥65 years) and younger (<65 years)
patients. The number of clinical and remodeling responders
was comparable, and we found no significant differences in
unplanned cardiac hospitalizations at 6 months between
groups. Independent predictors of lack of remodeling
response to CRT were QRS duration <120 ms, LV diastolic
diameter >74 mm, and JA >10 cm2 before CRT, but not
comorbidities.
Conclusion This work suggests that being elderly is not an
impediment to CRT success even in the presence of
comorbidities.
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1 Introduction
Heart failure (HF) is the fastest growing cardiovascular
disease, and it carries a poor prognosis even with optimal
pharmacotherapy [1]. The prevalence of HF increases
rapidly with age, the mean age of HF population being
around 75 years in developed countries [2, 3].
Cardiac resynchronization therapy (CRT) improves
symptoms and also reduces HF hospitalizations and all-
cause mortality when added to optimal pharmacotherapy in
patients in New York Heart Association (NYHA) class III
or IV, with reduced ejection fraction and a QRS width of at
least 120 ms. However, in almost all randomized clinical
trials, these results were demonstrated in selected patients,
with few older patients enrolled [4–6]. As a result, it is still
not completely clear whether elderly patients respond less
favorably or not to CRT as compared with younger patients.
Conventionally, the term “elderly” has been defined as a
chronological age of 65 years or older [7]. Recent studies have
suggested that elderly patients derive similar benefits from
CRT to younger patients [8–10]. Nevertheless, in these
works, the elderly population is quite different in terms of
chronological age: Foley et al. analyzed a population 80 or
more years old; Bleeker et al. used 70 as cutoff, and Delnoy
et al. studied a group older than 75 [8–11]. In addition, in
these studies, there was no reference to comorbidities [8–10]
or they were present in small rates in these older patients [11].
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The aim of our study was to compare the effects of CRT
in elderly patients (65 years or older) vs. younger patients
(64 years or younger) in terms of clinical and echocardio-
graphic parameters. We also aimed to assess the impact of
typical heart failure-associated comorbidities in reverse
remodeling and clinical response to CRT.
2 Methods
2.1 Inclusion criteria and study protocol
This is a prospective observational study that involved a single
center. The study population included 87 consecutive patients
with advanced HFwho underwent CRT fromNovember 2005
to October 2007. The majority of patients were in NYHA
functional class III or IV despite optimal medical treatment.
All patients had echocardiographic left ventricular (LV)
ejection fraction <35% and QRS duration >120 ms (with left
bundle branch block configuration) or QRS duration ≤120ms,
but mechanical dyssynchrony documented by tissue Doppler
echocardiography (intraventricular dyssynchrony >40 ms and
interventricular dyssynchrony >40 ms).
Patients were divided according to the chronological age
into younger (less than 65 years old) and elderly patients
(65 years old or older).
At baseline and 6 months after CRT, all patients
underwent a clinical and echocardiographic evaluation.
The clinical follow-up period was extended until 15th
August 2009 (mean follow-up of 28±12 months), with
hospital file review or direct telephone contact, and we
have recorded the occurrence of death, heart transplanta-
tion, and hospitalization for heart failure management.
Regarding assessed comorbidities, estimated creatinine
clearance (CrCl) was calculated with the Cockcroft–
Gault formula and renal dysfunction was defined as a
CrCl <60 ml/min. Hyperuricemia was defined as a serum
uric acid level >7.0 mg/dl in men or >6.0 mg/dl in
women. Patients with a body mass index of 30 kg/m2 or
higher were considered obese. We have also assessed
history of known diabetes and persistent atrial fibrillation.
The protocol was approved by our institutional
Research Ethics Committee, and all patients gave informed
consent.
2.2 Device implantation
The LV pacing lead was inserted by a transvenous approach
through the coronary sinus, with an over-the-wire system,
into either a lateral or posterolateral cardiac vein whenever
possible. The right atrium and right ventricle were
stimulated by positioning standard bipolar leads in the right
atrial appendage and right ventricular apex, respectively. A
combined device (CRT plus internal defibrillator) was
implanted in 64 patients (74%).
CRT device and lead implantation was successful in all
patients, without major complications.
2.3 Echocardiography
Standard echocardiography, including tissue Doppler imag-
ing (TDI), was performed using an ATL IDH 5500 Philips
System (Vingmed- General Electric, Horten, Norway)
before and 6 months after implantation of the biventricular
pacing device. LV dimensions were measured from M-
mode echocardiography in the parasternal long-axis view.
The LV end-diastolic volume (LVEDV), left ventricular
end-systolic volume (LVESV), and left ventricular ejection
fraction (LVEF) were assessed by the biplane Simpson’s
equation in apical four-chamber and two-chamber views.
Another measurement of systolic function evaluated was
dP/dt. In fact, it has been demonstrated that the mean rate of
Doppler-derived LV pressure rise during early systole
(determined by the 1- and 3-m/sec velocity points on the
rising segment of the continuous-wave mitral regurgitation
curve) correlated well with peak dP/dt obtained from LV
pressure curves at catheterization, although dP/dt may
underestimate the true values in a substantial number of
patients [12]. LV diastolic function was assessed with the
evaluation of LV inflow diastolic velocities with pulse-
wave Doppler (E and A velocities). We assessed the ratio of
peak flow velocity in early diastole and peak flow velocity
in late diastole during atrial contraction (E/A), the deceler-
ation time of E-wave (DTE), isovolumic relaxation time,
and the mitral regurgitation jet area (JA).
To assess dyssynchrony, time delay between the onset of
QRS complex on the surface electrocardiogram and the onset
of the systolic velocity wave on the TDI recording was
assessed in four basal LV segments (septal, lateral, anterior,
and inferior). Intraventricular dyssynchrony (TS-Intra-VD)
was calculated as the difference between the longest and
the shortest time delay in the four basal segments.
Interventricular dyssynchrony (TS-Inter-VD) was calcu-
lated as the difference between time to peak systolic
velocity at the right ventricle free wall and the most
delayed LV segment.
One single operator performed all echocardiographic
evaluations in order to avoid inter-individual variability.
2.4 Definition of CRT responders
At the 6 months of follow-up, patients were classified as
clinical responders to CRT if they were still alive, had not
been re-hospitalized for management of congestive heart
failure, and had a reduction of at least one NYHA class.
Regarding echocardiographic definition of response to
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CRT, a decrease in LVESV of at least 15% defined
remodeling responders [13].
2.5 Statistical analysis
Statistical analyses were performed using SPSS software
version 15. Results are expressed as mean ± standard
deviation (SD) for continuous variables and as counts and
percentages for categorical variables. Data were compared
with paired or unpaired Student’s t test when appropriate.
Nonparametric Mann–Whitney test was used for compari-
son of continuous variables between younger and elderly
patients when variables were not normally distributed.
Discrete variables were compared with the chi-square test
or with Fisher exact test whichever is appropriate.
Efficacy of CRT was examined by comparing baseline
vs. follow-up parameters using the Student’s paired t test
for comparisons of quantitative variables and by the
McNemar test for comparisons of qualitative variables.
Independent predictors of non-response to CRT were
identified by means of multivariable logistic regression.
The simultaneous effects of elderly and comorbidities on
non-response to CRT were examined. We entered into the
multivariable logistic regression model the following
variables: age over 65, renal dysfunction, diabetes, NYHA
IV at baseline, left atrium >47 mm, QRS duration <120 ms,
LVDD >74 mm, and JA >10 cm2.
The Kaplan–Meier method was used to compare heart
transplantation, death, or hospitalization for heart failure-
free survival between elderly and younger patients.
A p value <0.05 was considered statistically significant.
3 Results
3.1 Study population
There were 55 male (63%) and 32 female patients (37%). The
mean age was 62±11 years, with 51 younger patients (59%)
and 36 elderly patients (41%). In the overall population,
hyperuricemia was present in 49%, renal dysfunction in 38%,
diabetes in 20%, obesity in 19%, and atrial fibrillation in 15%
of patients. Baseline characteristics of the two age groups are
summarized in Table 1. Elderly patients had a significantly
higher prevalence of renal dysfunction (69.0% vs. 19.1%,
p<0.001) and tend to have more diabetes. They also had less
frequently a baseline QRS duration <120 ms (23.5% patients
in the younger group vs. 6.1% in the elderly group, p=0.040),
but LV dyssynchrony was similar in both groups (Table 1).
The elderly group received less frequently a combined device
(86% of the younger group vs. 56% of the elderly group,
p=0.003). The left ventricular lead was positioned in a lateral
or posterolateral vein in 73.3% of cases (75.0% of younger
vs. 66.7% of elderly patients, p=0.645).
Characteristics <65 years old (n=51) ≥65 years old (n=36) p value
Age 54.7±8.3 71.8±4.1 <0.001
Men/women (%) 66.7/33.3 58.3/41.7 0.501
NYHA class II 11.8 8.3 0.749
NYHA class III 64.7 72.2
IV 23.5% 19.5%
Ischemic/idiopathic (%) 33.3/66.7 38.9/61.1 0.653
QRS duration (ms) 141.2±33.1 150.0±28.4 0.212
Atrial fibrillation (%) 12.0 19.4 0.374
Diabetes (%) 13.7 29.4 0.077
Creatinine clearance (ml/min) 84.3±31.7 55.6±19.3 <0.001
BMI (kg/m2) 27.5±4.1 27.4±3.6 0.836
Uric acid (mg/dl) 6.7±2.0 6.5±2.3 0.763
LVEF (%) 23.9±6.3 24.4±7.1 0.746
LVEDV (ml) 278.3±118.4 246.6±85.7 0.174
LVESV (ml) 214.2±102.5 188.2±71.7 0.192
LV dP/dt (mmHg/ms) 477.5±186.6 479.7±129.7 0.955
JA (cm2) 7.9±5.9 7.6±5.1 0.821
E/A 1.4±0.8 1.1±0.5 0.097
DTE (ms) 169.6±62.5 174.6±70.3 0.323
Intraventricular dyssynchrony (ms) 81.7±46.2 84.2±56.2 0.821
Interventricular dyssynchrony (ms) 51.7±27.4 47.7±21.2 0.471
Table 1 Comparison of base-
line characteristics between
elderly and younger patients
NYHA New York Heart Associ-
ation, BMI body mass index,
LVEF left ventricular ejection
fraction, LVEDV left ventricular
end-diastolic volume, LVESV
left ventricular end-systolic
volume, LV left ventricular, JA
mitral regurgitation jet area, E/A
E/A ratio, DTE deceleration
time of E-wave
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3.2 Effects of CRT: 6 months of follow-up
After CRT implantation, there were significant improvements
of LVEF, LVESV, LV dP/dt, and JA in both age groups
(Table 2). Moreover, the magnitude of improvement of these
echocardiographic parameters was not significantly different
between groups. The reduction of LVESV was 24.1±43.1 ml
in the younger group vs. 26.2±52.5 ml in the elderly group
( p=0.838); the improvement of LVEF was 7.5±8.6% in the
younger group vs. 6.5±9.2% in the elderly group ( p=0.621);
the improvement of LV dP/dt was 180.2±348.6 mmHg/ms in
the younger vs. 217.7±269.1 mmHg/ms in the elderly group
( p=0.630); and reduction of JA was 1.8±3.2 cm2 in the
younger vs. 2.3±4.0 cm2 in the elderly group ( p=0.589).
The number of remodeling responders and of clinical
responders was comparable between younger and elderly
patients (Fig. 1). During the 6-month follow-up period, we
found no significant differences either in heart failure-driven
rehospitalization or in ICD shocks between groups (Fig. 1).
Only one patient underwent cardiac transplantation during
the follow-up, and another one died due to heart failure.
3.3 Predictors of non-response to CRT
In the overall population, the proportion of remodeling non-
responders to CRT was 46%. No significant differences
between remodeling responders and non-responders to CRT
were found regarding age, the incidence of diabetes, renal
dysfunction, hyperuricemia, obesity, and the presence of
ischemic cardiomyopathy. However, non-responders were
more frequently in NYHA class IV before CRT (32.5% vs.
13% in remodeling responders, p=0.038), presented more
frequently a QRS duration less than 120 ms (28% vs. 7%,
p=0.009), with significantly larger baseline left atrium,
higher LV dimensions and volumes, and greater mitral
regurgitation JA than remodeling responders (Table 3).
In multivariate logistic regression analysis, independent
predictors of non-response to CRT were baseline QRS
duration less than 120 ms, LVDD higher than 74 mm, and
JA over 10 cm2 before CRT (Fig. 2). Comorbidities were not
independent predictors of remodeling non-response to CRT.
In elderly patients, CRT response in terms of reverse
remodeling was correlated to E/A ratio, E-wave decelera-
tion time, LV dyssynchrony, and QRS duration. The E/A
ratio was inversely correlated with the reduction of LVESV
(r=−0.602, p=0.001). E-wave deceleration time, LV dyssyn-
chrony, and QRS duration were directly correlated with
LVESV reduction after CRT (r=0.377, p=0.026; r=0.418,
p=0.007; and r=0.378, p=0.021, respectively).
None of the studied comorbidities was correlated with
reverse remodeling after CRT in the elderly group.
3.4 Extended clinical follow-up
In the extended follow-up, the occurrence of heart transplan-
tation, hospitalization for heart failure management, or death
was verified in 27.6% of patients, with a mean time to this
event of 14±10 months. The Kaplan–Meier survival analysis
revealed no significant differences in event-free survival
curves between the elderly and the younger groups (Fig. 3).
Fig. 1 Clinical outcomes over the different age categories
Table 2 Echocardiographic response over the two age categories



















LVEF left ventricular ejection fraction, LVEDV left ventricular end-
diastolic volume, LVESV left ventricular end-systolic volume, JA
mitral regurgitation jet area, LV left ventricular
*p<0.05 (follow-up vs. baseline value)
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4 Discussion
Despite the encouraging results from CRT in recent trials,
patients’ responses to CRT vary significantly. Presently, it
remains unclear whether or not elderly patients, of the real
world, respond less favorably to CRT as compared with
younger patients. If age was a negative influence on clinical
outcome, this would be a good reason to restrict the use of
CRT in the elderly.
Previous studies have shown that elderly patients with HF
are a heterogeneous group and appear to differ substantially
from patients enrolled in clinical trials [14]. Comorbidity
complicates HF care and is prevalent in one form or another
for the majority of elderly patients scheduled for CRT. This
wide range of comorbidities, which includes diabetes and
renal dysfunction, contributes to the progression of HF and
may alter the response to treatment [15–17].
Previous data have demonstrated that the number and
severity of comorbid illnesses is a key factor in the overall
Table 3 Baseline characteristics of remodeling responders and non-
responders to cardiac resynchronization therapy
Responders Non-responders p value
Age 63±11 61±11 0.360
Men/women (%) 57/43 73/27 0.090
Baseline NYHA class (%)
II 15 5 0.050
III 72 62
IV 13 33
QRS duration (ms) 150±30 139±33 0.110
Atrial fibrillation (%) 17.8 12.5 0.559
Ischemic/idiopathic (%) 34.8/65.2 35.0/65.0 0.983
Diabetes (%) 23.9 15.8 0.356
Renal dysfunction (%) 36.6 41.2 0.684
Obesity (%) 22.2 12.8 0.392
Hyperuricemia (%) 53.1 43.8 0.453
Left atrium (mm) 43±9 47±8 0.020
LVDD (mm) 71±7 79±11 <0.001
LVSD (mm) 59±7 67±12 0.001
LVEDV (ml) 237±73 296±130 0.009
LVESV (ml) 181±63 227±112 0.020
LVEF (%) 28±10 24±6 0.168
JA (cm2) 6.0±4.8 9.9±5.8 0.001
LV dyssynchrony (ms) 84.5±57.6 80.4±41.7 0.710
NYHA New York Heart Association, LVDD left ventricular diastolic
diameter, LVSD left ventricular systolic diameter, LVEDV left
ventricular end-diastolic volume, LVESV left ventricular end-systolic
volume, LVEF left ventricular ejection fraction, JA mitral regurgitation
jet area, LV left ventricular
OR CI 95% p  value
0.79 0.184 – 3.375 0.749 
13.80 2.266 – 84.036 0.004 
4.83 1.288 – 18.142 0.020 
4.62 1.090 – 19.553 0.038 
3.11 0.723 – 13.359 0.128 
1.89 0.440 – 8.127 0.391 
1.61 0.441 – 5.847 0.473 
0.79 0.178 – 3.510 0.758 
Age > 65 yo 
QRS < 120 ms 
LVDD > 74 mm 
JA > 10 cm 2 
NYHA IV 
Renal dysfunction 
LA > 47 mm 
Diabetes 
0 1   5             10            15            20 
Fig. 2 Multivariate logistic re-
gression analysis of predictors
of non-response to cardiac
resynchronization therapy
















Age > or = 65
Age < 65
Elderly
p = 0.655 
Fig. 3 Kaplan–Meier event-free survival of patients aged ≥65 and
patients aged <65 years
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survival of patients as well as the benefits of therapy [18].
So, we could ask: could comorbidities be an impediment to
clinical and echocardiographic response to CRT?
In “the real world” clinical practice, elderly patients
referred to CRT usually present comorbidities that distin-
guish them from the perfect candidate enrolled in clinical
trials. Previous studies have looked at the impact of
individual comorbidities or composite scores on mortality
after CRT rather than their impact on CRT response [19, 20].
In fact, there are no studies that have examined the impact
of comorbidities such as diabetes, renal dysfunction,
obesity, and hyperuricemia on echocardiographic response
to CRT, particularly in elderly patients. To the best of our
knowledge, we were the first to do so.
4.1 Patient population
Several baseline characteristics of our study population
were consistent with those of patients enrolled in previous
CRT clinical trials, such as a predominance of male gender
and NYHA functional class III, a marked systolic dysfunc-
tion as revealed by reduced LVEF, a severe LV dilatation,
and a prolonged QRS duration. However, in our “real
world” population, we had more patients over 65 years old
than in previously published clinical trials [4, 6, 21–23].
In the elderly group, we observed several comorbidities
that suggest that elderly patients were not selected on the
basis of a special good clinical status.
4.2 Clinical outcome
At the 6-month follow-up visit, CRT resulted in significant
benefits in both age categories, as evidenced by the
improvement in clinical and echocardiographic parameters.
CRT resulted in a significant improvement in LVEF and a
left ventricular reverse remodeling. Moreover, the number of
clinical and remodeling responders to CRT was similar in
both groups, and there were no significant differences in
unplanned cardiac hospitalizations within 6 months of CRT,
thus supporting the hypothesis of an inducible favorable
clinical effect and reverse remodeling even in older patients.
4.3 Impact of comorbidities
To the best of our knowledge, no data about the impact of
comorbidities like renal dysfunction, obesity, and hyperuri-
cemia in CRT response have been reported before.
One of the most important comorbidities in HF is renal
dysfunction, and it is an important independent predictor of
mortality and morbidity among this population [16].
Previous studies have indicated that CRT can be considered
a renal-protective strategy in HF and that the improvement
in renal function can be another mechanism to explain the
beneficial effects of CRT [24–26]. Nevertheless, there are
no studies in the literature that addressed the impact of renal
dysfunction on the efficacy of CRT in terms of left
ventricular reverse remodeling.
In our study, renal dysfunction tended to be slightly more
prevalent in non-responders. However, in multivariate analysis,
it was not a predictor of non-response to CRT. Even in elderly
patients who had a higher prevalence of renal dysfunction, it
seems not to prevent the positive response to CRT.
Heart failure and diabetes are strongly associated, and
each condition represents a risk factor for the development of
the other. Additionally, the presence of diabetes is a powerful
independent predictor of morbidity and mortality among
patients with HF [27]. The pathophysiology underlying HF
in diabetic patients differs from that of non-diabetic
patients, and it has been questioned whether CRT is equally
beneficial in patients with and without diabetes. In
accordance with previous studies, in our work, diabetes
was not a predictor of poor response to CRT [28, 29].
Serum uric acid is intensively correlated with circulating
markers of inflammation in patients with chronic HF and is
a strong independent predictor of mortality. Inflammatory
markers reflect HF severity, so we could speculate that high
uric acid levels could be associated with a poor response to
CRT. However, in our population, the proportion of
hyperuricemic patients in remodeling responders was
similar or even higher than that of non-responders.
Obesity represents an important risk factor for overall
mortality and for development of HF in the general
population [30]. Nevertheless, in patients with chronic HF,
obesity appears to be associated with a favorable prognosis
[31–34]. The underlying pathophysiology of this “obesity
paradox” is still poorly understood. In the CRT setting, no
previous studies have examined whether obesity affects or
not the ability of left ventricular reverse remodeling. Our
study is the first to do so, and it suggests that obesity is not
an impediment to CRT positive response.
A recent meta-analysis of prospective cohort studies
concluded that patients in atrial fibrillation show significant
improvement after CRT, with similar or improved ejection
fraction as sinus rhythm patients [35]. In accordance with
previous study, in our work, atrial fibrillation did not appear
to be a predictor of non-response to CRT.
In our work, comorbidities were not predictors of poor
response to CRT, neither in the overall population nor in
elderly patients.
4.4 Predictors of non-response to CRT
In our study, we included some patients with narrow QRS
and mechanical dyssynchrony documented by echocardi-
ography because at the beginning of this study, the results
of the RethinQ study, providing evidence that patients with
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HF and narrow QRS intervals may not benefit from CRT,
were not yet known [36]. In our work, the stronger
predictor of non-response to CRT was QRS less than
120 ms, which is in accordance with the results of the
RethinQ study and suggests that CRT should not be offered
to patients with a narrow QRS even if they present
significant echocardiographic intraventricular dyssyn-
chrony. LV dilatation and severe mitral regurgitation were
the other predictors of lack of response, underlying the
importance of LV geometry in reverse remodeling after
CRT. It seems that patients with advanced forms of dilated
cardiomyopathy are worse candidates for CRT than patients
in the earlier phases of the disease.
In the elderly, mechanical dyssynchrony, again, seems to
be crucial to a positive CRT response. In addition, in these
patients, parameters of diastolic function were important
factors for reverse remodeling. In our study, higher E/A
ratios were associated with poor response to CRT, empha-
sizing the importance of cardiac compliance to achieve
reverse remodeling.
4.5 Study limitations
This is a single-center, observational cohort study. The most
important limitations of this study are the small number of
patients included and the relatively short period of follow-up.
Additionally, this work presents typical limitations of non-
randomized studies that are a potential bias in patient’s
selection.
Another limitation of this study is the classification of
diabetes that was made on the basis of medical history
obtained from patients during the baseline visit interview;
information on diabetic medications or diabetes control was
not collected. Moreover, we did not ascertain cases of
diabetes that developed during the study follow-up.
4.6 Clinical implications
Our work indicates that old age is not a reason for
excluding patients from CRT. In fact, our study suggests
that even elderly patients with comorbidities, but with good
life expectancy, can benefit from CRT.
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